42 Ha'Yarkon Street
145 articles with MediWound
EMA Accepts MediWound’s Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns
MediWound Ltd. today announced that the European Medicines Agency (EMA) has validated for review the Type II Variation submitted by MediWound in order to expand the current approved indication for NexoBrid (removal of eschar in adults with deep partial-and full-thickness thermal burns.
MediWound’s NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress
MediWound Ltd. announced its successful and meaningful presence at the recently concluded 19th European Burns Association Congress held in Turin, Italy on September 7-10, 2022.
This week’s Movers & Shakers include Scribe, Appia Bio, Chimerix and KemPharm, all announcing new VP roles. Companies also plan for the future with the implementation of a succession plan.
MediWound Ltd. today announced financial results for the second quarter ending June 30, 2022.
MediWound Ltd. announced the appointments of Mr. Nachum Shamir as the Chairman of the Company’s Board of Directors and Dr. Robert Snyder as the Company’s Chief Medical Officer.
MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
MediWound Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its recently re-submitted Biologics License Application (BLA) for NexoBrid ® for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.
MediWound Schedules Second Quarter 2022 Financial ResultsConference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET
MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that the Company will release its financial results for the second quarter ended June 30, 2022 on Tuesday, August 9, 2022.
Kyowa Kirin announced it is dropping its Parkinson’s disease candidate, KW-6356, a follow-up to Nourianz, despite promising Phase II data that showed the drug is "potentially effective."
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced an oral presentation at the Advanced Wound Care Summit taking place on July 13-14, 2022 in Boston, MA.
MediWound to Host a Key Opinion Leader Investor Day on EscharExIn-Person KOL Breakfast Meeting to be held on Tuesday, July 12th in New York City
MediWound Ltd. announced that it will host an in-person key opinion leader event on EscharEx for analysts and investors on Tuesday, July 12, 2022 at 8:00 am Eastern Time at the St. Regis Hotel in New York, NY.
Entering the second half of 2022, biopharma and life sciences companies from across the globe strengthen their leadership teams with new additions to the c-suite.
MediWound Ltd. announced Financial results for the first quarter ended March 31, 2022.
MediWound Ltd. announced the appointment of Ofer Gonen as Chief Executive Officer of MediWound as of June 30, 2022, succeeding Sharon Malka, who will join the Company's Board of Directors.
MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
MediWound Ltd. announced positive results from its U.S. Phase 2 clinical study of EscharEx® for the debridement of venous leg ulcers.
MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022
MediWound Ltd. announced that the Company will release its financial results for the first quarter ended March 31, 2022 on Tuesday, May 17, 2022.
Australia’s Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors. Switzerland-based CDR-Life closed a $76 million Series A.
MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that clinical data from the Company’s EscharEx® phase 2 trials was highlighted in a poster and oral presentation at the 35th Symposium on Advanced Wound Care Spring Conference.
MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022
MediWound Ltd. announced a poster and oral presentation of its EscharEx® clinical data at the 35th Symposium on Advanced Wound Care Spring Conference taking place in Phoenix, Arizona on April 6-10, 2022.
MediWound Ltd., a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, announced that the underwriter of its recently completed public offering of ordinary shares, which closed on March 7, 2022, partially exercised their over-allotment option, having purchased an additional 623,082 ordinary shares.
MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds
MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the last patient in its U.S. Phase 2 clinical study of EscharEx® for the debridement of venous leg ulcers (VLUs) has completed the study treatment visits as well as the required follow up.